# Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants

> **NCT00197275** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 800 (—)

## Conditions studied

- Tetanus
- Hepatitis B
- Haemophilus Influenzae Type b
- Whole Cell Pertussis
- Diphtheria

## Interventions

- **BIOLOGICAL:** Hib-MenAC mixed with Tritanrix™-HepB

## Key facts

- **NCT ID:** NCT00197275
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** 800 (—)
- **Last updated:** 2016-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00197275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00197275, "Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00197275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*